The pathophysiological role of LTs in several inflammatory conditions and, particularly, in asthma is well documented, and several molecules, named LT modifiers, able to interfere with the LT biosynthetic cascade or with the LT receptors, have been approved for the treatment of asthma [46]. This evidence concerns the gene LTA and asthma.